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de equal contributAbstract Cajanine, a constituent of Cajanaus cajan L., used in traditional Chinese medicine, is a
promising drug candidate because of its broad range of bioactivities. However, the total synthesis of
cajanine and its derivatives has never been reported. Herein, we report the total synthesis of cajanine in
nine steps with an overall yield of 10% together with its analog, longistyline A, in 8% yield. The
antiproliferative activity of the two compounds against a human hepatoma cell line is also reported.
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Xing-yue Ji et al.941. Introduction
Cajanine, also known as longistyline A-2-carboxylic acid, is a
stilbene derivative (Fig. 1) isolated from the herb Cajanus cajan
L1,2. The herb has been used in traditional Chinese medicine for
many years to treat osteonecrosis of the femoral head.
Cajanine is a good drug candidate because of its wide range
of pharmacological activities, which include antitumor3, anti-
HSV4, antihyperlipidemic5,6, anti-osteoporotic7,8, hypoglyce-
mic9 and antioxidant10 effects. Recently, it was also reported
that cajanine can modulate Ab25–35-induced cognitive deﬁcits,
oxidative stress and cholinergic dysfunction in mice11. Despite
its evident potential as a therapeutic agent, the total synthesis
of cajanine and its derivatives has not been reported. We
herein report the total synthesis of cajanine and its analog
longistyline A for the ﬁrst time.2. Chemistry
Our retrosynthetic analysis of cajanine is shown in Scheme 1.
The starting material, compound 2, can be readily synthe-
sized using the method of Kato et al.12 in 45% yields shown in
Scheme 2.
Compound 3 was obtained by methylation of compound 2
with MeI. Because 2-OH and 1-COOMe of compound 2
participate in hydrogen bonding, the acidity of the 2-OH group
is weaker than that of the 4-OH group. Consequently, the 4-OH
group is more nucleophilic and compound 3a is obtained as an
intermediate product, which subsequently transforms into com-
pound 3 as the reaction proceeds (Scheme 3).
The bromination of compound 3 in the presence of an equi-
molar amount of Br2 or NBS failed to give compound 4 butCOOH
HO
OMe
1: Cajanine
Figure 1 Structure of cajanine.
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Scheme 1 Retrosyntheticinstead produced compound 4a (Scheme 4) whose structure
was conﬁrmed by both 1H NMR and an NOE experiment. This
may be attributed to the activation of the benzene ring by the
two methoxy substituents. Compound 4a was obtained in even
greater yield by carrying out the reaction at 0 1C.
In view of these results, we modiﬁed the synthetic route to
the sequence of reactions shown in Scheme 5.
To brominate compound 3 both in the benzene ring and at
the benzylic position, NBS or Br2 (two equivalents) was used.
To obtain a product with the trans conﬁguration product in
the Horner–Wadsworth–Emmons reaction, P(OEt)3 rather
than Ph3P was chosen to react with 4b to give compound
5a. This was reacted with benzaldehyde under the conditions
of the Horner–Wadsworth–Emmons reaction but compound
6a (Scheme 6) was obtained in rather low yield (20%).
Accordingly we ﬁrst debrominated compound 5a using the
method of Zask and Helquist13 prior to the Horner–
Wadsworth–Emmons reaction. However, a mixture of pro-
ducts was obtained leading us to adopt the method of Chen
et al.14, which produced compound 5 in high yield (90%).
Compound 5 was then reacted with benzaldehyde under
the conditions of the Horner–Wadsworth–Emmons reaction
to afford compound 6 in a relatively high yield (85%). The
double bond in 6 and 6a was assigned to the E conﬁguration
based on the high coupling constant (16.0 Hz) between the
alkene double bond hydrogens in the 1H NMR spectrum.
The selective demethylation of the 2-OMe group in com-
pound 6 was accomplished using BCl3. The reaction is
facilitated by the fact that the 2-OMe group and the ortho
carbonyl group in COOMe form a chelate with boron
(Scheme 7). Compound 7 was obtained in high yield (95%),
and its structure was conﬁrmed by 1H NMR and an NOE
experiment in which irradiation of the hydroxyl hydrogenCOOMe
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Total synthesis antiproliferative activity of cajanine 95enhanced the intensity of 3-H (d¼6.40 ppm) of the benzene
ring but not that of 5-H (d¼6.79 ppm).
Compound 8 was synthesized in acceptable yield (60%) by
the coupling reaction of prenyl bromide with the sodium salt
of compound 7 in toluene as solvent. A major byproduct of
the reaction was the product of O-alkylation of the 2-OH
group. The ﬁnal step in the synthesis of 1 involved the
hydrolysis of the ester group of 8, which, because of steric
hindrance, took more than 24 h to complete. However, the
reaction time was reduced to 1 h when a microwave was used.
The overall yield of cajanine was 10.9%. During the ﬁnal
hydrolysis reaction, the decarboxylation product 9 (longisty-
line A)1,2 (Fig. 2), which, like cajanine, is a constituent of
Cajanus cajan L. was also formed and isolated in 8% yield.3. Antiproliferative activity
The antiproliferative activity of cajanine and longistyline A
was examined in human hepatoma Bel-7402 cells using the
standard MTT assay. The results are summarized in Table 1.
In comparison with the positive control, vincristine, both
cajanine and longistyline A exhibited weak antiproliferative
activity against Bel-7402 cells. The IC50 values of longistyline
A and cajanine were similar, indicating that the carboxyl
group in cajanine has little effect on the growth inhibitory
activity in Bel-7402 cells.4. Experimental procedures
4.1. Chemical synthesis
All reagents and solvent were purchased from commercial
sources. THF, toluene and DME were distilled from sodium
and benzophenone before use. CCl4, CH2Cl2, CH3CN weredistilled from P2O5. All reactions were carried out in ﬂame-
dried glassware and monitored by thin layer chromatography.
NMR spectra were recorded in CDCl3 or DMSO-d6 using a
Varian Inova 400 MHz spectrometer (Varian, San Francisco,
CA, USA). Chemical shifts are reported in parts per million
relative to tetramethylsilane as internal standard. Melting
points were determined using an X6 microscope melting point
apparatus and are uncorrected. The microwave experiment
was conducted using a Discover-s microwave oven (CEM,
Matthews, NC, USA).
4.1.1. Methyl 2,4-dihydroxy-6-methylbenzoate (2)
This was synthesized using the method of Kato et al.12 m.p.
137–139 1C. IR (thin ﬁlm) umax 3366.8, 3311.0, 2978.5, 2957.8,
1640.1, 1582.0, 1445.6, 1324.9, 1267.2, 1169.4, 1159.9, 952.9,
853.7, 837.3, 800.2, 702.6 cm1. 1H NMR (400 MHz, DMSO-
d6, 25 1C, TMS) d: 10.66 (s, 1H), 9.95(s, 1H), 6.15 (d,
4J¼2.4 Hz, 1H), 6.14 (d, 4J¼2.4 Hz, 1H), 3.78 (s, 3H), 2.65
(s, 3H). 13C NMR (100 MHz, CDCl3) d: 172.10, 165.30,
160.17, 144.00, 111.28, 105.71, 101.26, 51.88, 24.24. MS(EI)
[M]þ¼182. HRMS(EI) calcd. for C9H10O4 [M]þ 182.0579,
found 182.0589.
4.1.2. Methyl 2-hydroxy-4-methoxy-6-methylbenzoate (3a)
Compound 2 (12 g, 0.066 mol) was dissolved in acetone
(100 mL) and anhydrous K2CO3 (27.29 g, 0.198 mol) and
MeI (28.12 g, 0.198 mol) were added. The mixture was heated
under reﬂux for 30 min, cooled to room temperature and
ﬁltered. The ﬁltrate was concentrated under reduced pressure
and the residue dissolved in ether. The insoluble solid was
ﬁltered and the ﬁltrate concentrated to give a residue, which
was puriﬁed over silica gel (petroleum ether:ethyl acetate 12:1)
to give compound 3a (9.0 g, 70%) as a colorless solid. m.p.
63–64 1C. IR (thin ﬁlm) umax 3010.7, 2981.7, 2948.3, 1648.2,
1615.6, 1442.5, 1326.6, 1267.5, 1203.6, 1155.1, 1405.5, 951.9,
866.5, 814.7, 696.2 cm1. 1H NMR (400 MHz, DMSO-d6, 25 1C,
TMS) d: 10.60 (s, 1H), 6.32 (d, 4J¼2.4 Hz, 1H), 6.30 (d,
4J¼2.4 Hz, 1H), 3.79 (s, 3H), 3.72 (s, 3H), 2.29 (s, 3H). 13C
NMR (100 MHz, CDCl3) d: 172.17, 165.52, 163.91, 143.07,
111.12, 105.22, 98.66, 55.25, 51.78, 24.30. MS(EI) [M]þ¼196.
HRMS(EI) calcd. for C10H12O4 [M]
þ 196.0736, found 196.0748.
4.1.3. Methyl 2,4-dimethoxy-6-methylbenzoate (3)
Compound 2 (12 g, 0.066 mol) was dissolved in CH3CN
(100 mL) and anhydrous K2CO3 (27.29 g, 0.198 mol) and
MeI (28.12 g, 0.198 mol) were added. The mixture was heated
under reﬂux for 8 h, cooled to room temperature and ﬁltered.
The ﬁltrate was concentrated under reduced pressure and the
residue was dissolved in ether. The insoluble solid was ﬁltered
and the ﬁltrate concentrated to give a residue, which was
puriﬁed over silica gel (petroleum ether:ethyl acetate 6:1)
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Scheme 5 Total synthesis of cajanine.
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Xing-yue Ji et al.96to give compound 3 (13.2 g, 95%) as a colorless solid. m.p. 34–
36 1C. IR (thin ﬁlm) umax 3005.0, 2951.0, 2841.0, 1726.0, 1606.5,
1586.4, 1326.0, 1266.0, 1199.0, 1157.3, 1093.8, 1053.3, 942.4,
844.1, 810.5, 640.7 cm1. 1H NMR (400 MHz, CDCl3, 25 1C,
TMS) d: 6.31 (s, 2H), 3.88 (s, 3H), 3.79 (s, 6H), 2.28 (s, 3H). 13C
NMR (100 MHz, CDCl3) d: 168.70, 161.35, 158.193, 138.26,
116.38, 106.63, 96.16, 55.88, 55.32, 52.01, 19.92. MS(EI)
[M]þ¼210. HRMS(EI) calcd. for C11H14O4 [M]þ 210.0892,
found 210.0894.4.1.4. Methyl 3-bromo-4,6-dimethoxy-2-methylbenzoate (4a)
Compound 3 (18 g, 0.085 mol) was dissolved in dry CCl4
(250 mL), and heated under reﬂux in a N2 atmosphere. A mix-
ture of NBS (15.1 g, 0.085 mol) and DBPO (1.0 g, 0.004 mol)
was added in portions and the mixture was reﬂuxed for
another 1 h. The reaction mixture was cooled, ﬁltered and
the ﬁltrate was concentrated to give a residue, which was
recrystallized from MeOH to give compound 4a (23.1 g, 95%)
as a colorless solid. m.p. 117–118 1C. IR (thin ﬁlm) umax
2971.0, 2951.1, 1720.9, 1592.4, 1465.9, 1332.6, 1269.8, 1211.8,
1075.3, 938.6, 818.9, 687.0 cm1. 1H NMR (400 MHz, CDCl3,
25 1C, TMS) d: 6.37 (s, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 3.83
(s, 3H), 2.34 (s, 3H). 13C NMR (100 MHz, CDCl3) d: 168.15,
157.42, 156.54, 137.10, 117.77, 105.74, 93.94, 56.39, 56.13,
52.36, 20.52. MS(EI) [M]þ¼288. HRMS(EI) calcd. for
C11H13O4Br
79 [M]þ 287.9997, found 287.9989; calcd. for
C11H13O4Br
81 [M]þ 289.9977, found 289.9973.4.1.5. Methyl 3-bromo-2-(bromomethyl)-4,6-
dimethoxybenzoate (4b)
Compound 3 (18 g, 0.085 mol) was dissolved in 40 mL dry
CCl4 (300 mL) and heated under reﬂux in a N2 atmosphere.
A mixture of NBS (30.2 g, 0.17 mol) and DBPO (2.0 g,
0.008 mol) was added in portions after which it was reﬂuxed
for another 1 h. The reaction mixture was cooled, ﬁltered and
the ﬁltrate was concentrated to give a residue, which was
recrystallized from anhydrous MeOH to give compound 4b
(25.3 g, 81%) as a white solid. m.p. 117–118 1C. IR (thin ﬁlm)
umax 2952.1, 2841.0, 1724.0, 1587.7, 1460.6, 1430.6, 1341.3,
1262.2, 1210.5, 1089.1, 1078.7, 949.1, 818.1, 681.8, 611.5 cm1.
1H NMR (400 MHz, CDCl3, 25 1C, TMS) d: 6.46 (s, 1H), 4.66
(s, 2H), 3.94 (s, 3H), 3.93 (s, 3H), 3.85 (s, 3H). 13C NMR
(100 MHz, CDCl3) d: 167.02, 158.05, 157.30, 136.29, 117.53,
105.85, 96.42, 56.55, 56.36, 52.62, 29.74. MS(EI) [M]þ¼370.
HRMS(EI) calcd. for C11H12O4Br
79Br81 [M]þ 367.9082; found
367.9084.4.1.6. Methyl 3-bromo-2-((diethoxyphosphoryl)methyl)-4,6-
dimethoxybenzoate (5a)
A mixture of compound 4b (12 g, 0.033 mol) and P(OEt)3
(13.1 g, 0.06 mol) was heated under reﬂux for 2 h. The excess
P(OEt)3 was then evaporated and the residue was puriﬁed over
silica gel (petroleum:acetone 2:1) to give compound 5a (12.6 g,
90%) as a white solid. m.p. 94–95 1C. IR (thin ﬁlm) umax
2976.3, 2908.5, 1707.6, 1588.8, 1432.9, 1336.2, 1262.8, 1219.7,
1043.2, 1023.7, 964.2, 956.5, 866.7, 826.6, 804.0, 788.7,
687.0 cm1. 1H NMR (400 MHz, CDCl3, 25 1C, TMS) d:
6.43 (s, 1H), 4.04 (m, 4H), 3.92 (s, 3H), 3.90 (s, 3H), 3.85 (s,
3H), 3.78 (d, 2J (H, P)¼22.8 Hz, 2H), 1.26 (t, 3J¼6.8 Hz, 6H).
13C NMR (100 MHz, CDCl3) d: 167.33, 157.94, 132.90,
117.42, 107.05, 95.26, 62.18, 62.11, 56.41, 56.37, 52.29,
31.95, 30.57, 16.36, 16.30. MS(EI) [M]þ¼424. HRMS(EI)
calcd. for C15H22O7PBr
79 [M]þ 424.0287, found 424.0249;
calcd. for C15H22O7PBr
81 [M]þ 426.0266, found 426.0260.
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Table 1 Antiproliferative activity of cajanine and long-
istyline A against human hepatoma Bel-7402 cells.
Compound IC50 (mmol/L)
Cajanine 19.14
Longistyline A 24.65
Vincristine 0.005
Total synthesis antiproliferative activity of cajanine 974.1.7. Methyl 2-((diethoxyphosphoryl)methyl)-4,6-
dimethoxybenzoate (5)
Compound 5a (20 g, 0.054 mol) was dissolved in n-BuOH
(100 mL) followed by the addition of Pd(OAc)2 (0.25 g,
1.1 mmol), Ph3P (1.14 g, 4.4 mmol) and K2CO3 (14.9 g,
0.11 mol). The mixture was stirred under reﬂux for 8 h after
which it was ﬁltered and the ﬁltrate was concentrated. The
residue was puriﬁed over silica gel (petroleum:acetone 2:1) to
give a white solid, which was recrystallized from ethyl acetate/
petroleum ether to afford compound 5 (16.8 g, 90%) as a
colorless solid. m.p. 71–72 1C. IR (thin ﬁlm) umax 2981.0,
2950.3, 2925.6, 1705.0, 1608.2, 1587.8, 1430.0, 1333.0, 1281.0,
1257.0, 1243.0, 1209.8, 1164.8, 1048.8, 1022.5, 973.1, 954.5,
811.4, 803.1, 792.4, 742.0, 501.3 cm1. 1H NMR (400 MHz,
CDCl3, 25 1C, TMS) d: 6.56 (t,
4J¼2.0 Hz, 1 H), 6.37 (s, 1H),
4.03 (m, 4H), 3.88 (s, 3H), 3.81 (s, 3H), 3.79 (s, 3H), 3.29 (d, 2J
(H, P)¼22.4 Hz, 2H), 1.25 (t, 3J¼7.2 Hz, 6H). 13C NMR
(100 MHz, CDCl3) d: 167.85, 161.39, 158.84, 132.81, 116.53,
107.16, 97.75, 62.15, 62.08, 55.98, 55.40, 52.04, 31.78, 30.42,
16.34, 16.28. MS(EI) [M]þ¼346. HRMS(EI) calcd. for
C15H23O7P [M]
þ 346.1181, found 346.1162.
4.1.8. (E)-methyl 2, 4-dimethoxy-6-styrylbenzoate (6)
Compound 5 (12 g, 0.035 mol) was dissolved in dry DME
(200 mL) followed by the addition of NaH (1.26 g, 0.037 mol)
and PhCHO (3.9 g, 0.037 mol) at room temperature. The
resulting mixture was heated under reﬂux in a N2 atmosphere
for 1 h and then added into ice water and extracted with ether.
The combined ether layer was dried over anhydrous MgSO4,
ﬁltered and concentrated. The residue was recrystallized from
ethyl acetate/petroleum ether to afford compound 6 (8.9 g,
85%) as colorless needles. m.p. 75–77 1C. IR (thin ﬁlm) umax3011.5, 2947.1, 1721.1, 1597.2, 1577.7, 1454.9, 1274.5, 1253.3,
1199.4, 1155.5, 1097.5, 1077.6, 1044.9, 948.5, 829.1, 734.0,
690.9 cm1. 1H NMR (400 MHz, DMSO-d6, 25 1C, TMS) d:
7.53 (d, 3J¼7.2 Hz, 2H), 7.38 (t, 3J¼7.2 Hz, 2H), 7.28 (m, 2H),
6.95(d, 4J¼2.4 Hz, 1H), 6.94(d, 3J¼16.0 Hz, 1 H), 6.58 (d,
4J¼2.4 Hz, 1H), 3.86 (s, 3H), 3.82 (s, 3H), 3.77 (s, 3 H).
13C NMR (100 MHz, CDCl3) d: 168.45, 161.54, 158.27,
137.58, 136.87, 131.75, 128.68, 128.08, 126.79, 125.45, 115.98,
101.54, 98.06, 56.02, 55.49, 52.32. MS(EI) [M]þ¼298.
HRMS(EI) calcd. for C18H18O4 [M]
þ 298.1205, found 298.1202.
4.1.9. (E)-methyl 3-bromo-4.6-dimethoxy-2-
styrylbenzoate (6a)
Compound 5a (10.0 g, 0.024 mol) was dissolved in dry DME
(200 mL) followed by the addition of NaH (0.86 g, 0.025 mol,
70% in mineral oil) and PhCHO (2.70 g, 0.025 mol) at room
temperature. The resulting mixture was heated under reﬂux in a
N2 atmosphere for 1 h after which most of the DME was
evaporated, ice water was added and the solution was extracted
with ether. The combined ether layer was dried over anhydrous
MgSO4, ﬁltered and concentrated to give a residue, which was
puriﬁed over silica gel (petroleum ether:ethyl acetate 8:1) to afford
compound 6a (1.8 g, 20%) as a white solid. m.p. 106–107 1C. IR
(thin ﬁlm) umax 2941.5, 2841.1, 1726.6, 1583.6, 1566.7, 1350.3,
1208.9, 1105.0, 1079.5, 972.2, 804.6, 759.6, 693.5 cm1. 1H NMR
(400MHz, CDCl3, 25 1C, TMS) d: 7.41 (d,
3J¼7.2 Hz, 2H), 7.28
(t, 3J¼7.2 Hz, 2H), 7.22 (t, 3J¼7.2 Hz, 1H), 7.11 (d, 3J¼16.0 Hz,
1H), 6.65 (d, 3J¼16.0 Hz, 1H), 6.39 (s, 1H), 3.88 (s, 3H), 3.81 (s,
3H), 3.70 (s, 3H). 13C NMR (100MHz, CDCl3) d: 167.82, 157.35,
156.95, 138.03, 136.69, 134.44, 128.66, 128.23, 126.78, 126.69,
116.75, 104.51, 95.10, 56.52, 56.30, 52.48. MS(EI) [M]þ¼376.
HRMS(EI) calcd. for C18H17O4Br
79 [M]þ 376.0310, found
376.0293; calcd. for C18H17O4Br
81 [M]þ 378.0290, found 378.0284.
4.1.10. (E)-methyl 2-hydroxy-4-methoxy-6-
styrylbenzoate (7)
Compound 6 (6.0 g, 0.02 mol) was dissolved in dry CH2Cl2
(100 mL) and BCl3 in CH2Cl2 (21 mL, 1 mol/L) added at
78 1C. The reaction mixture was stirred for 1 h at 78 1C
after which it was quenched by the addition of ice water.
The organic layer was separated and dried over anhydrous
MgSO4, ﬁltered and concentrated to give a residue, which was
recrystallized from petroleum ether to give compound 7 (5.3 g,
95%) as a colorless solid. m.p. 107–109 1C. IR (thin ﬁlm) umax
3081.7, 3000.7, 2941.7, 2848.5, 1650.5, 1605.8, 1437.5, 1329.1,
1268.6, 1220.4, 1198.4, 1161.7, 1054.6, 972.1, 964.0, 847.4,
803.4, 750.3, 697.0 cm1. 1H NMR (400 MHz, DMSO-d6,
25 1C, TMS) d: 10.28 (s, 1H), 7.52 (d, 3J¼7.2 Hz, 2H), 7.38
(t, 3J¼7.2 Hz, 2H), 7.28 (t, 3J¼7.2 Hz, 1H), 7.16 (dd,
3J¼16.0 Hz, 2H), 6.79 (d, 4J¼2.4 Hz, 1H), 6.40 (d, 4J¼2.4
Hz, 1H), 3.82 (s, 3H), 3.79 (s, 3H). 13C NMR (100 MHz,
Xing-yue Ji et al.98CDCl3) d: 171.65, 165.14, 164.15, 142.85, 137.40, 130.86,
129.84, 128.74, 127.82, 126.65, 107.98, 103.98, 100.20, 55.47,
52.25. MS(EI) [M]þ¼284. HRMS(EI) calcd. for C17H16O4
[M]þ 284.1049, found 284.1027.4.1.11. (E)-methyl 2-hydroxy-4-methoxy-3-(3-methylbut-2-
enyl)-6-styrylbenzoate (8)
Compound 7 (2.0 g, 7.0 mmol) was dissolved in dry toluene
(50 mL) and NaH (0.25 g, 7.4 mmol, 70% in mineral oil) was
added at room temperature. The reaction mixture was stirred
at room temperature for 0.5 h after which a portion of the
toluene was evaporated and prenyl bromide (1.25 g, 8.4 mmol)
was added at room temperature. The mixture was stirred for
2 h at 35 1C, quenched by the addition of ice water and the
organic layer separated and dried over anhydrous MgSO4. It
was then ﬁltered and concentrated to give a residue, which was
puriﬁed over silica gel (petroleum ether:ether 20:1) to give a
crude product, which was recrystallized from petroleum ether
to afford compound 8 (1.48 g, 60%) as a white solid. m.p.
100–102 1C. IR (thin ﬁlm) umax 3025.8, 2971.1, 2949.0, 2914.4,
2853.3, 1649.3, 1601.6, 1560.6, 1438.6, 1277.4, 1219.4, 1193.0,
1153.0, 1111.9, 1001.2, 977.0, 807.4, 757.2, 696.3 cm1.
1H NMR (400 MHz, DMSO-d6, 25 1C, TMS) d: 10.66 (s,
1H), 7.55 (m, 3H), 7.39 (t, 3J¼7.2 Hz, 2H), 7.28 (t, 3J¼7.2 Hz,
1H), 7.08 (d, 3J¼16.0 Hz, 1H), 6.85 (s, 1H), 5.10 (t, 3J¼7.2
Hz, 1H), 3.90 (s, 3H), 3.88 (s, 3H), 3.25 (d, 3J¼7.2 Hz, 2H),
1.71 (s, 3H), 1.61 (s, 3H). 13C NMR (100 MHz, CDCl3) d:
171.94, 161.45, 161.34, 140.31, 137.52, 131.85, 130.65, 130.06,
128.74, 127.71, 126.57, 122.07, 116.68, 104.55, 102.86, 55.65,
52.23, 25.81, 22.13, 17.80. MS(EI) [M]þ¼352. HRMS(EI)
calcd. for C22H24O4 [M]
þ 352.1675, found 352.1646.4.1.12. Cajanine (1) and longistyline A (9)
Compound 8 (0.5 g, 1.42 mmol) was dissolved in absolute EtOH
(15 mL) and KOH (0.25 g, 4.26 mmol) was added. The mixture
was placed in a sealed vessel and subjected to microwave
irradiation (30 W, 90 1C, 21 psi) for 1 h maintaining the tempera-
ture at 9071 1C. The reaction mixture was then added into ice
water (50 mL) and the pH was adjusted to 2 with 10% HCl
followed by extraction with ethyl acetate (3 25 mL). The
combined organic layer was dried over anhydrous MgSO4,
ﬁltered and concentrated to give a residue, which was recrystal-
lized from CH2Cl2/petroleum ether to give compound 1 (0.38 g,
80%) as a white solid. m.p. 168–170 1C. The mother liquor was
puriﬁed over silica gel (petroleum ether:ethyl acetate 10:1) to give
compound 9 (33 mg, 8%) as a white solid. m.p. 71–72 1C.
Compound 1: IR (thin ﬁlm) umax 3058.5, 2961.3, 2928.4,
2851.5, 1632.7, 1600.0, 1440.9, 1274.7, 1222.6, 1117.3, 962.9,
820.9, 744.9, 688.8 cm1. 1H NMR (400 MHz, CDCl3, 25 1C,
TMS) d: 11.58 (s, 1H), 7.81 (d, 3J¼16.0 Hz, 1H), 7.52 (d,
3J¼7.2 Hz, 2H), 7.38 (t, 3J¼7.2 Hz, 2H), 7.28 (t, 3J¼7.2 Hz,
1H), 6.83 (d, 3J¼16.0 Hz, 1H), 6.65 (s, 1H), 5.22 (t, 3J¼6.8
Hz, 1H), 3.95 (s, 3H), 3.38 (d, 3J¼6.8 Hz, 2H), 1.79 (s, 3H),
1.68 (s, 3H), COOH was not observed. 13C NMR (100 MHz,
CDCl3) d: 174.95, 162.44, 162.25, 141.77, 137.28, 131.97,
130.86, 130.34, 128.74, 127.89, 126.79, 121.89, 116.77, 103.29,
102.97, 55.73, 25.82, 22.09, 17.80. MS(ESI) [2MþNa]þ¼ 699.1,
[MþNa]þ¼361.0. HRMS(ESI) calcd for C21H22O4Na [Mþ
Na]þ 361.14158, found 361.14318.
Compound 9: IR (thin ﬁlm) umax 3557.6, 2995.0, 2912.8,
1605.8, 1582.8, 1422.1, 1163.7, 1086.9, 966.2, 822.1, 751.1,693.6 cm1. 1H NMR (400 MHz, CDCl3, 25 1C, TMS) d: 7.50
(d, 3J¼7.2 Hz, 2H), 7.35 (t, 3J¼7.2 Hz, 2H), 7.28 (t, 3J¼7.2
Hz, 1H), 7.02 (dd, 3J¼16.0 Hz, 2H), 6.66 (s, 1H), 6.64 (s, 1H),
5.24 (m, 2H), 3.87 (s, 3H), 3.41 (d, 3J¼6.8 Hz, 2H), 1.82 (s,
3H), 1.75 (s, 3H). 13C NMR (100 MHz, CDCl3) d: 183.32,
158.08, 155.49, 137.28, 136.65, 134.53, 128.65, 128.37, 127.55,
126.47, 121.81, 115.00, 107.14, 101.57, 55.81, 25.80, 22.36,
17.85. MS(EI) [M]þ¼294. HRMS(EI) calcd. for C20H22O2
[M]þ 294.1620, found 294.1606.4.2. Pharmacology
4.2.1. Drugs
Cajanine and longistyline A (purity495%) were dissolved in
DMSO to give 10 mg/mL stock solutions, which were further
diluted in medium before use. Vincristine was purchased from
Sigma (No. 398 Weihai Road, Shanghai, China).4.2.2. Cell line
The human hepatoma cell line Bel-7402 was obtained from the
Cancer Institute, Chinese Academy of Medical Sciences. Cells
were cultured in RPMI 1640 (Invitrogen) supplemented with
10% fetal bovine serum, 100 units/mL penicillin and 100 mg/mL
streptomycin. The culture was maintained at 37 1C under 5%
CO2 in a humidiﬁed atmosphere.4.2.3. Antiproliferative assay
Cell viability was assessed in the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide assay. Cells were seeded into
96-well microplates at 1 104 per well followed by the
addition of cajanine and longistyline A solutions at concen-
trations in the range 0–10 mg/mL and incubation for 72 h at
37 1C. Supernatants were gently removed and cell viability was
assessed using a microplate reader. The IC50 was determined
in duplicate and each experiment was repeated at least three
times under identical conditions. IC50, deﬁned as the drug
concentration that inhibits 50% cell growth compared with
the untreated controls, was calculated by regression analysis.5. Conclusions
Cajanine was synthesized for the ﬁrst time in nine steps in an
acceptable yield of 10.9%. All intermediates are reported for
the ﬁrst time except compounds 2, 3a, 3 and 4a. Longistyline
A was also obtained in 8% yield. Both cajanine and longisty-
line A were shown to have weak growth inhibitory activity
against human hepatoma Bel-7402 cells. This work will
facilitate future structure–activity relationship (SAR) studies
of cajanine or longistyline A in the search for novel drug
candidates.Acknowledgment
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